ERBB2 and breast carcinoma: Most recently, T-DXd received FDA approval for the treatment of adult patients with unresectable, or metastatic HER2-low breast cancer, after treatment with prior chemotherapy or after disease recurrence within six months of completing adjuvant chemotherapy [155].